

Aadel A Chaudhuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672383/publications.pdf>

Version: 2024-02-01

38
papers

4,971
citations

471371

17
h-index

414303

32
g-index

42
all docs

42
docs citations

42
times ranked

7354
citing authors

#	ARTICLE	IF	CITATIONS
1	Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA. <i>Theranostics</i> , 2022, 12, 362-378.	4.6	21
2	Circulating Tumor DNA Minimal Residual Disease Detection of Non-“Small-Cell Lung Cancer Treated With Curative Intent. <i>Journal of Clinical Oncology</i> , 2022, 40, 567-575.	0.8	83
3	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
4	Liquid biopsy<i> AR</i>/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 171-171.	0.8	0
5	LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. <i>Radiotherapy and Oncology</i> , 2022, 167, 317-322.	0.3	10
6	Integrative analysis of urine cell-free DNA for the detection of residual disease in localized bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 559-559.	0.8	0
7	Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses. <i>Molecular Cancer</i> , 2022, 21, 73.	7.9	16
8	Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-“Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules. <i>JCO Precision Oncology</i> , 2022, 6, e2100378.	1.5	5
9	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Cancer Research</i> , 2022, 82, 2838-2847.	0.4	14
10	Human papillomavirus DNA resides in surgical drain fluid exosomes from HPV+ oropharyngeal squamous cell carcinoma patients and can be spread to neighboring HPV-negative cells.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18050-e18050.	0.8	0
11	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. <i>Translational Research</i> , 2021, 231, 124-138.	2.2	11
12	Colonosight: Multitarget RNA-FIT assay for noninvasive detection of advanced colorectal neoplasia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	0.8	0
13	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	1.5	26
14	Integrated clinicopathologic and molecular risk stratification for disease recurrence in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 490-490.	0.8	0
15	Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasia in a Multicenter, Prospective, and Retrospective Cohort. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00360.	1.3	2
16	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003732.	3.9	38
17	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. <i>PLoS Medicine</i> , 2021, 18, e1003734.	3.9	35
18	Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 757-774.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	0.6	147
20	Reply. <i>Gastroenterology</i> , 2020, 158, 793-794.	0.6	0
21	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
22	Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. <i>JCO Precision Oncology</i> , 2020, 4, 806-817.	1.5	7
23	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	1.5	20
24	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
25	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
26	Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 165-177.	0.4	19
27	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
28	AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5529-5529.	0.8	0
29	Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15545-e15545.	0.8	1
30	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
31	Noninvasive Detection of High-Risk Adenomas Using Stool-Derived Eukaryotic RNA Sequences as Biomarkers. <i>Gastroenterology</i> , 2019, 157, 884-887.e3.	0.6	9
32	Stereotactic ablative radiotherapy for central and ultra-central lung tumors. <i>Therapeutic Radiology and Oncology</i> , 2019, 3, 18-18.	0.2	3
33	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	9.4	2,396
34	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
35	Local consolidative therapy for oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 5649-5651.	0.6	2
36	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. <i>Cancer Discovery</i> , 2019, 9, 500-509.	7.7	143

#	ARTICLE	IF	CITATIONS
37	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
38	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. <i>Seminars in Radiation Oncology</i> , 2015, 25, 305-312.	1.0	97